Italy reviews diagnostics in Chikungunya alert
This article was originally published in Clinica
Italy is reviewing its diagnostics capacity, in response to an outbreak of Chikungunya. Over the last two months, suspected cases have been rising - around 200 at September 6, according to the health ministry - and laboratory testing has so far confirmed the presence of the virus in at least 20% of cases. The outbreak is centred in the province of Ravenna, in the north of the country, where the Emilia Romagna regional health authority has been closely monitoring all potential cases since July.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.